PCV61 THE FRENCH CV@GOAL EDUCATIONAL PROGRAM FOR IMPROVING HBP MANAGEMENT BY PATIENTSAND PHYSICIANS: ASSESSMENT OF ITS IMPACT ON PATIENT'S KNOWLEDGE AND PATIENT-PHYSICIAN RELATIONSHIP  by Mosqueda, Jasso et al.
A107Abstracts
According to these ﬁndings, treatment with 160mg valsartan/
25mg HCTZ totally dominates and it should be preferable. Sen-
sitivity analysis conﬁrmed the results from this base case.
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OBJECTIVES: Hypertension is a highly prevalent risk factor for
cardiovascular disease (CVD), which affects approximately 50
million Americans. The outcome data from several clinical trials
and meta-analyses prove that new and old classes of antihyper-
tensive drugs provide similar reductions of cardiovascular mor-
bidity and mortality. The purpose of this study was to compare
the costs associated with the prescription of ﬁrst-line anti-
hypertensive agents in United States (US). METHODS: A cost-
minimization analysis was performed. A decision analysis model
was developed to compare the ﬁve alternative interventions:
chlorthalidone, propranolol, amlodipine, enalapril and losartan.
Clinical inputs were derived from randomized controlled trials
and cost data from 2004 Red Book and Centers for Medicare &
Medicaid Services. The evaluation of the cost of managing mild-
to-moderate hypertension includes the cost of drug therapy,
monitoring, treating side-effects, poor compliance and switching.
All costs were calculated from a health system’s perspective, in
2004 $US. Future costs and clinical beneﬁts were discounted at
5%. The time horizon was 5 years. RESULTS: The total cost to
achieve and maintain hypertension control in US setting was
$2194.42, $3181.79, $3566.36, $2885.69 and $3747.57 for
chlorthalidone, propranolol, amlodipine, enalapril and losartan
respectively. The drug acquisition cost was 27.54%, 51.28%,
58.18%, 47.83%, and 61.55% respectively. Sensitivity analysis
tested the effect of modifying the prices of the antihypertensive
agents and laboratory monitoring, the doses of the alternative
drugs and the compliance rate on the economic endpoints and
conﬁrmed the superiority of chlorthalidone. CONCLUSIONS:
In patients with mild-to-moderate hypertension in US, treatment
costs to prevent CVD are much lower with chlorthalidone than
with the other ﬁrst-line antihypertensive agents.
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Despite therapeutic advances, High Blood Pressure (HBP)
remains a health issue in Western countries. Few programs have
sought to improve physician-patient relationship and the effect
of educating HBP patients. CV@Goal is a French educational
programme (2002 to 2003) aimed at training physicians to
educate HBP patients. OBJECTIVES: Assessing the impact of
CV@Goal on HBP patients and physicians. METHODS: A 6-
month before-after comparison of physician and HBP patient
populations. Four HBP patients per GPs were included. GPs were
trained to educate HBP patients and included four new HBP
patients. RESULTS: In total, 1208 HBP patients and 308 physi-
cians completed the “before” questionnaire, and after training
512 new patients and 169 physicians completed the “after” ques-
tionnaire. According to GPs, there were in both phases “impor-
tant” or “insurmountable difﬁculties” concerning patient seden-
tary lifestyle (40%), diet compliance (60%) and alcohol (75%).
The proportion of GPs who considered patient knowledge to be
“good” or “very good” increased for: general issues (22% to
38%), the disease natural history (8% to 14%), risks (29% to
49%), complication prevention (13% to 24.5%) and alarm
symptoms (21% to 35%); the proportion also increased for
patient awareness of the importance of smoking cessation (69%
to 77%) and special dieting (52% to 67%). Changes in patients’
blood pressure were not signiﬁcant. Most patients believed
smoking, diabetes, alcohol, hypercholesterolemia, treatment
compliance, obesity, age, heredity and diet could alter blood
pressure; knew HBP could relate to heart, brain, arteries, eyes,
kidneys complications; that smoking cessation, weight loss,
physical exercise and salt reduction could improve HBP. After
CV@Goal, improvements were observed in patient knowledge
about the importance of weight loss, physical exercise and salt
consumption. Nevertheless, most patients declare they have not
changed lifestyle since the HBP diagnosis. CONCLUSION:
CV@Goal had an impact on patient knowledge about HBP, but
not on lifestyle and BP.
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OBJECTIVES: Hypertensive patients with cardiovascular (CV)
disease or diabetes are at a particularly high CV risk. LDL-
cholesterol (cLDL) levels are an important CV risk factor and
total cholesterol/cHDL (TC/HDL) ratio is also related to car-
diovascular risk. Although HDL-cholesterol (cHDL) is a protec-
tive factor, available therapeutic strategies are not effective
enough. The objective of this study is to compare cLDL, cHDL
and TC/HDL between two groups: patients with previous CV
disease/diabetes and those without it in a hypertensive popula-
tion from a programme for CV risk control. METHODS: A total
of 5094 subjects from primary care centres in Spain were retro-
spectively studied. Levels of cLDL, cHDL and TC/HDL were
compared for the above mentioned groups by Student t test for
independent samples. RESULTS: There were 41.4% men. Mean
age 66.3 years. Average TC levels were: 214.4mg/dL; cLDL:
141.9mg/dL; cHDL: 45.5mg/dL and TC/HDL: 4.98. Levels of
cLDL were signiﬁcantly lower for those with CV disease/dia-
betes: 148.6mg/dL (SD 32.8) vs. 132.3mg/dL (SD 35); p <
0.0001. Similarly, Levels of cHDL were signiﬁcantly lower 
for those with CV disease/diabetes: 47.1mg/dL (SD 12.5) vs.
43.1mg/dL (SD 11.4): p < 0.0001. There were no signiﬁcant dif-
ferences of CT/HDL ratio between groups. CONCLUSIONS: In
a population of treated hypertensives, cLDL levels are lower for
those with previous CV disease/diabetes, which is appropriate
taking into account their higher cardiovascular risk. On the con-
trary cHDL levels are lower in the group at highest risk. There
is a wide room for improvement of cardiovascular risk in hyper-
tensive patients with previous CV disease or diabetes, by increas-
ing HDL.
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